BeiGene
NASDAQ:BGNEBiotechBeijing, China, China · Est. 2010 · 7,000 employees
BeiGene is a Chinese biotechnology company developing innovative oncology and hematology treatments for both Western and Chinese markets.
13
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
17
Indications↗
Distinct diseases across all programs
156
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
13 drugs in development
Phase 34
Phase 26
Phase 15
Preclinical4
By Therapeutic Area
top 2
Oncology
1179%
Immunology
17%
R&D Momentum
59/100
Pipeline Velocity
6/100
Trial Completion Rate
86/100
Pipeline Concentration
64/100
Pipeline Freshness
59/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 15, 2026
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Sep 12, 2026
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Sep 12, 2026
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Sep 12, 2026
Active, not recruiting
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Sep 10, 2026
Recruiting
A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria and in Healthy Participants
Earlier
Sep 3, 2026TrialPhase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma
Sep 2, 2026TrialA Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Aug 29, 2026TrialAn Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
4 more events
Aug 25, 2026TrialA Phase 1, Open-label, Fixed-sequence, Crossover Study to Investigate the Effect of Coadministration of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-16673 in Healthy Participants
Aug 25, 2026TrialA Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors
Aug 22, 2026TrialA Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
Aug 13, 2026TrialPhase 1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in the First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Details
Company Info
Company Overview
$18.0B
Mkt Cap
$1.5B
Revenue
—
Cash
CEOJohn V. Oyler
Founded2010
Employees7,000
HQBeijing, China, China
ExchangeNASDAQ:BGNE
Websitebeigene.com
LinkedInCompany Page
Therapeutic Focus
OncologyOtherNephrologyRespiratoryImmunology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology(1 drug)
—
—
1
—
—
Immunology(1 drug)
Oncology(11 drugs)
4
4
5
4
—
Oncology(11 drugs)
Unknown / Other(2 drugs)
—
1
1
—
—
Unknown / Other(2 drugs)
Regulatory
Regulatory Timeline
20231 event
FDAJul 17
Beyfortus — BEYFORTUS
Application BLA761328
20242 events
FDAAug 22
Beyfortus — BEYFORTUS
Application BLA761328
FDAFeb 23
Beyfortus — BEYFORTUS
Application BLA761328
20251 event
FDAOct 20
Beyfortus — BEYFORTUS
Application BLA761328
20261 event
FDAApr 7
Beyfortus — BEYFORTUS
Application BLA761328
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)